Olshan advised Ronin Trading and SW Investment Management on the matter
Pursuant to the agreement, all four of Peregrine’s long-standing incumbent directors resigned and were replaced with four new independent directors, including three designated by Ronin Trading/SW Investment Management. Following the agreement, Peregrine has a seven-member Board consisting of entirely new directors from when Ronin Trading and SW Investment Management launched their campaign for change in July 2017. Ryan Nebel represents Ronin Trading and SW Investment Management in connection with their investment in Peregrine Pharmaceuticals.
Olshan advised with a team led by Ryan Nebel (Picture).
Involved fees earner: Ryan Nebel – Olshan Frome Wolosky LLP;
Law Firms: Olshan Frome Wolosky LLP;